Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
SCORED: Sotagliflozin shows robust MACE benefit
Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the...
News
FDA okays semaglutide higher dose, 2 mg/week, for type 2 diabetes
The 2-mg weekly dose is associated with greater A1c reduction and more weight loss.
News
Empagliflozin scores topline win in EMPA-KIDNEY trial
Researchers stopped the 6,600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial...
News
Finerenone + SGLT2 inhibitor of benefit in diabetes with CKD?
Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors...
News
Older age for menopause raises risk for lung cancer
This is the first study that has shown a causal association between older age of natural menopause and higher risk of postmenopausal lung cancer...
News
Uptake uncertain for potent new LDL-lowerer inclisiran
Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its U.S. debut in early 2022 with cautious uptake prospects.
News
Benign adrenal tumors linked to hypertension, type 2 diabetes
Benign adrenal tumors produce enough cortisol to cause hypertension or type 2 diabetes in more than 15% of patients in a prospective U.K. study....
News
More lots of metformin recalled
A further 33 lots of extended-release metformin 750-mg tablets have been voluntarily recalled by Viona because of possible contamination.
News
Type 2 diabetes remission can happen naturally in 1 in 20
About 1 in 20 people in Scotland who had previously been diagnosed with type 2 diabetes were in remission in 2019, usually without a history of an...
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
News
Oral daprodustat safely improves anemia in chronic kidney disease
“What’s out there [for daprodustat] seems very encouraging,” according to a nephrologist.
